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private and public sources, and was unclear in the remaining 3. There
were no randomized controlled trials evaluating auto-HCT in CLL.
Five studies were single-arm trials and 3 were non-randomized trials
with a control arm (autologous vs. allogeneic). Median age for pts
receiving auto-HCT ranged from 45 to 59 years. When allogeneic
HCT was the control arm, the median age ranged from 40 to 47
years. The cumulative number of pts receiving auto-HCT is 403 (M
294, F 109). Primary endpoints in the trials were: CR (clinical or
molecular) 4; OS2; PFS1; engraftment1. Median clinical re-
sponse rates from 6 studies ranged from 54.5 % to 89.4% at 3 to 20
months. Molecular response in one study was 76.9%. Overall survival
at 3 to 6 years in 4 studies were 88.6% to 58%. Median progression-
free survival in 3 studies were 92.3 % at 4 years to 30% at 6 years.
Conclusion: The evidentiary base to recommend HDT and auto-
HCT as standard practice in CLL is limited. Improved response rates,
especially molecular responses are encouraging. It is uncertain
whether auto-HCT is superior to CC as a salvage strategy, but data
appears promising to take it to a formal testing in a randomized study.
Table 1:
Studies identiﬁed in Medline and hand-search of references
(N82)
Not included (N74) [Reviews18, Not clinical outcome17,
not clinical trial13, not transplant trial12, not CLL8, not in
English3, prognostic-marker studies3]
Eligible studies (N8) [single-arm trials5, non-randomized
comparison3]
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AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION: REGIMEN RE-
LATED COMPLICATIONS AND TRANSPLANT OUTCOME
Kumar, L.1, Ganessan, K.1, Khatry, N.1, Sengar, M.1, Sharma, A.1
1All India Institute of Medical Sciences, New Delhi, India.
Purpose : To determine the transplant related complications
after autologous peripheral blood stem cell transplantation (ASCT)
and overall outcome.
Design : Cohort study of 144 consecutive patients.
Setting : A tertiary care centre
Patients and Methods : 144 consecutive patients (median age 47.5
years, range, 11 to 68 years) underwent ASCT. There were 102 males
and 42 females. Indications for transplant were : multiple myeloma-
78(54.2%), Hodgkin’s-14(9.7%), non Hodgkin’s lymphoma-
14(9.7%), acute leukemia 17, CML -5(3.5%), solid tumours
-16(10.7%). Patients received G-CSF mobilized peripheral blood
stem cells (PBSC). All patients were treated in a single room with
reverse barrier nursing without laminar air ﬂow or HEPA ﬁlter. High
dose (HD) chemotherapy was given using standard protocols . Organ
toxicity was assessed according to Seattle criteria and response to
transplant as per standard guidelines.
Results : 126 of 144 patients engrafted. 19 (13.2%) patients died
prior to day 30. The causes of death were sepsis with or without
multi-organ failure (n-12) and regimen related toxicity-7 (4.2%). Fac-
tors like poor performance status , progressive or refractory disease at
transplant and failure to engraft by day 18 were associated with
increased risk of day 30 mortality. GIT toxicity, mucositis, veno-
occlusive disease, liver and renal dysfunction were main regimen
related toxicities; GIT toxicity and mucositis was signiﬁcantly higher
among patients who received HD melphalan for conditioning. Post
transplant, CR rate was signiﬁcantly higher in chemosensitive disease
group (70%) compared to 20% in chemo-refractory disease, p.01.
The median overall survival (OS) for all patients is 55 months 
9.07(CI 37.22-72.78) with estimated OS at 2 and 5 years being 66.5%
and 45%, respectively. Event - free survival (EFS) for the whole group
is 24 months  5.13(13.94-34.06) with probability of EFS 2 and 5
years being 47.2 %, and 41%, respectively . Survival was signiﬁcantly
better for patients with chemo-sensitive disease at transplant (median
OS 89 months vs 18 months,p.0001). Patients who were in CR post
transplant had a signiﬁcantly better overall survival . Currently, 60 of
126 patients (47.6%) are alive at a median follow up of 3 years. 66
patients have died predominantly due to relapse - 57/66 (86.4%).
Conclusion : Good primary pre-transplant management and
careful case selection are two important factors associated with
good transplant outcome.
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RITUXIMAB-RELATED LATE-ONSET NEUTROPENIA AFTER AUTOLO-
GOUS STEM CELL TRANSPLANTATION FOR MALIGNANT LYMPHOMA
Nagafuji, K.1, Numata, A.1, Yoshimoto, G.1, Harada, N.1,
Harada, M.1 11st Dep of Internal Medicine, Kyushu University Hospi-
tal, Fukuoka, Japan.
Rituximab (Rit) chimeric human/mouse monoclonal antibody
directed against the CD20 antigen. It can be used before stem cell
harvest as a way of in vivo purging or after stem cell transplantation
as an adjuvant therapy.
Recently, several cases of late-onset neutropenia (LON) have
been described in relation to its utilization in stem cell transplan-
tation as well as chemotherapy setting.
The reason why Rit induces neutropenia was poorly understood.
Dunleavy reported that perturbation of SDF-1 during B-cell re-
covery retards neutrophil egress from the bone marrow as a mech-
anism of Rit-induced neutropenia (Blood, Vol. 106, 795-802).
We retrospectively analyzed the incidence of LON in autologous
peripheral blood stem cell transplantation (autoPBSCT) for malig-
nant lymphoma (ML) using Rit, autoPBSCT forMLwithout Rit, and
autoPBSCT of CD34 cells for refractory autoimmune disease (AD).
Methods
LON was deﬁned as neutrophil count less than 1,000/l after
achieving durable hematopoietic engraftment without apparent
reasons including myelotoxic drug, viral infection, or disease pro-
gression. The hematologic data of out patient clinics were retro-
spectively analyzed.
Results
The incidence of LON was 64.3% in autotransplanted ML with
Rit. The Nadir of LON was 69-751 (median 578) /l. The onset
of LON from transplant was 61-128 (median 80) days. The dura-
tion of LON was 14-124 (median 56) days. There were no LON-
related infectious complications.
The incidence of LON of autotransplanted ML without Rit and
autotransplanted AD was 8.3%, and 10%, respectively.
Conclusion When Rit was used peri-autotransplant period, the
incidence of LON was increased. Since autotransplantation with
puriﬁed CD34 cells did not increase the incidence of LON, our
analysis results could not support the idea that perturbation of
SDF-1 during B-cell recovery retards neutrophil egress from the
bone marrow as a mechanism of Rit-induced neutropenia.
Results AD using
CD34
cells
(n10)
ML with Rit
(n14)
ML without Rit
(n12)
age(median) 14-59(54) 31-68(50) 21-63
(54)
sex (M/F) 7 / 7 10 / 2 3 / 7
disease DLBL 12, FL 2 DLBL 6, PTCL
2, LBL 1, MCL
1, 2
SSc 7,
SLE 1,
DM/IP 1,
WG 1
disease status 1CR 11, 1Rel
2, 2CR 1
1CR 8, 1PR 2,
Ref 2
No. of infused
CD34 cells
7.4 (3.9 -13.9)
10e6/kg
8.3 (1.4-24.5)
10e6/kg
4.9 (2.0
-16.0) )
10e6/kg
Conditioning R-MCEC 10,
MCEC 3, 2
MCEC 10, TBI
1, 1
HD-CY
LON 9 (64.3%) 1(8.3%) 1(10%)
Neutoropenia of
known reason
VZV 2 Drug 1 CMV 1
observation period
(median)
121-929 (276) 148-1715 (860)
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